T
Tae-You Kim
Researcher at New Generation University College
Publications - 79
Citations - 7354
Tae-You Kim is an academic researcher from New Generation University College. The author has contributed to research in topics: Chemotherapy & Lung cancer. The author has an hindex of 38, co-authored 79 publications receiving 7031 citations. Previous affiliations of Tae-You Kim include Howard Hughes Medical Institute & University of Florida.
Papers
More filters
Journal ArticleDOI
Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein
Michael Ohh,Cheol Won Park,Cheol Won Park,Mircea Ivan,Michael A. Hoffman,Tae-You Kim,Tae-You Kim,L. Eric Huang,Nikola P. Pavletich,Nikola P. Pavletich,Vincent Chau,William G. Kaelin,William G. Kaelin +12 more
TL;DR: It is shown that pVHL, through its β-domain, binds directly to hypoxia-inducible factor (HIF), thereby targeting HIF for ubiquitination in an α-domain-dependent manner, the first function to be ascribed to the pV HL β- domain.
Journal ArticleDOI
Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib
Sae-Won Han,Tae-You Kim,Pil Gyu Hwang,Soohyun Jeong,Jeongmi Kim,In Sil Choi,Do Youn Oh,Jee Hyun Kim,Dong Wan Kim,Doo Hyun Chung,Seock-Ah Im,Young Tae Kim,Jong-Seok Lee,Dae Seog Heo,Yung-Jue Bang,Noe Kyeong Kim +15 more
TL;DR: P-Akt overexpression was associated with prolonged TTP in patients with EGFR mutation, which further support the importance of EGFR mutations with regard to gefitinib sensitivity.
Journal ArticleDOI
Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies.
Tae-You Kim,Dong Wan Kim,Jae-Yong Chung,Sang Goo Shin,Sung-Chul Kim,Dae Seog Heo,Noe Kyeong Kim,Yung-Jue Bang +7 more
TL;DR: The main dose-limiting toxicities were neuropathy, myalgia, and neutropenia, and the recommended dosage for a phase II study is 300 mg/m2, which suggests that Genexol-PM has linear pharmacokinetics.
Journal ArticleDOI
Histone Deacetylase Inhibitors for Cancer Therapy
TL;DR: New insights into the molecular mechanism of HDACIs are discussed, their current status of clinical development, and possible future uses in cancer therapy are discussed.
Journal ArticleDOI
Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation
Sae-Won Han,Tae-You Kim,Yoon Kyung Jeon,Pil Gyu Hwang,Seock-Ah Im,Kyung-Hun Lee,Jee Hyun Kim,Dong Wan Kim,Dae Seog Heo,Noe Kyeong Kim,Doo Hyun Chung,Yung-Jue Bang +11 more
TL;DR: In addition to EGFR mutation, K-ras mutation and Akt phosphorylation aid in better prediction of gefitinib responsiveness in non–small-cell lung cancer.